Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$131.59
-0.2%
$131.03
$110.86
$141.23
$229.51B0.75.52 million shs6.08 million shs
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
$12.04
+6.4%
$10.49
$7.80
$28.09
$617.65MN/A305,071 shs332,393 shs
Evotec AG stock logo
EVO
Evotec
$3.49
-2.2%
$3.97
$2.84
$5.64
$1.27B1.6748,454 shs30,323 shs
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$7.50
-1.1%
$7.74
$3.85
$8.98
$609.79M1.25493,817 shs205,479 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
-0.29%+1.31%+4.34%-0.68%+17.16%
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-4.39%-1.31%-3.66%+13.43%+1,131,999,900.00%
Evotec AG stock logo
EVO
Evotec
-1.92%-2.99%-16.20%-16.59%+6.57%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-3.19%-4.89%-9.44%+48.92%+81.77%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.8991 of 5 stars
2.54.04.24.52.52.52.5
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
1.5877 of 5 stars
3.50.00.00.00.80.80.6
Evotec AG stock logo
EVO
Evotec
1.5274 of 5 stars
3.32.00.00.01.60.00.6
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
4.564 of 5 stars
3.54.00.04.82.72.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.91
Moderate Buy$144.479.79% Upside
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
3.00
Buy$32.25167.87% Upside
Evotec AG stock logo
EVO
Evotec
2.50
Moderate Buy$5.4054.73% Upside
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
3.00
Buy$24.00220.00% Upside

Current Analyst Ratings Breakdown

Latest EVO, ABT, BCAX, and MGTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/22/2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$41.00 ➝ $40.00
8/18/2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$36.00
8/15/2025
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00
8/14/2025
Evotec AG stock logo
EVO
Evotec
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $7.00
8/12/2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$30.00
7/18/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$147.00 ➝ $142.00
7/18/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$142.00 ➝ $141.00
7/18/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$148.00 ➝ $145.00
7/18/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$143.00 ➝ $145.00
7/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/16/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$130.00 ➝ $140.00
(Data available from 8/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$43.11B5.31$6.57 per share20.03$29.20 per share4.51
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/AN/AN/AN/A$7.98 per shareN/A
Evotec AG stock logo
EVO
Evotec
$862.40M1.44N/AN/A$2.70 per share1.29
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$33.28M18.13N/AN/A$0.04 per share187.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$13.40B$7.9816.4922.972.5032.43%18.32%10.71%10/15/2025 (Estimated)
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-$68M-$3.17N/AN/AN/AN/A-21.67%-20.89%11/11/2025 (Estimated)
Evotec AG stock logo
EVO
Evotec
-$212.18MN/A0.00N/AN/A-20.14%-16.94%-8.14%11/5/2025 (Estimated)
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$147.79M-$2.04N/A19.74N/A-415.39%-314.44%-63.28%11/12/2025 (Estimated)

Latest EVO, ABT, BCAX, and MGTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$0.52-$0.48+$0.04-$0.48$8.00 million$3.69 million
8/12/2025Q2 2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-$0.54-$0.50+$0.04-$0.50N/AN/A
7/17/2025Q2 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.26$1.26N/A$1.01$11.01 billion$11.14 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.361.79%N/A29.57%54 Years
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/AN/AN/AN/AN/A
Evotec AG stock logo
EVO
Evotec
N/AN/AN/AN/AN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
N/AN/AN/AN/AN/A

Latest EVO, ABT, BCAX, and MGTX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/13/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.591.73%7/15/20257/15/20258/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.25
1.82
1.30
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/A
25.80
25.80
Evotec AG stock logo
EVO
Evotec
0.42
1.58
1.49
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
26.29
0.88
0.88

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/A
Evotec AG stock logo
EVO
Evotec
5.81%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
67.48%

Insider Ownership

CompanyInsider Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.46%
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/A
Evotec AG stock logo
EVO
Evotec
N/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
7.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
114,0001.74 billion1.73 billionOptionable
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
3254.56 millionN/AN/A
Evotec AG stock logo
EVO
Evotec
4,827355.11 millionN/ANot Optionable
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
30080.45 million74.41 millionOptionable

Recent News About These Companies

MeiraGTx Sales Jump 1,133 Percent
MeiraGTx Holdings plc (MGTX) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abbott Laboratories stock logo

Abbott Laboratories NYSE:ABT

$131.59 -0.28 (-0.21%)
Closing price 03:59 PM Eastern
Extended Trading
$131.65 +0.06 (+0.05%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Bicara Therapeutics stock logo

Bicara Therapeutics NASDAQ:BCAX

$12.04 +0.72 (+6.36%)
Closing price 04:00 PM Eastern
Extended Trading
$12.24 +0.21 (+1.70%)
As of 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Evotec stock logo

Evotec NASDAQ:EVO

$3.49 -0.08 (-2.24%)
Closing price 04:00 PM Eastern
Extended Trading
$3.52 +0.02 (+0.72%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

MeiraGTx stock logo

MeiraGTx NASDAQ:MGTX

$7.50 -0.08 (-1.06%)
Closing price 04:00 PM Eastern
Extended Trading
$7.29 -0.21 (-2.79%)
As of 05:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.